Apollo Endosurgery inks agreement for up to $100 million term loans

By Wendy Van Sickle

Columbus, Ohio, Dec. 21 – Apollo Endosurgery, Inc. entered into a loan agreement on Tuesday with Innovatus Life Sciences Lending Fund I, LP as collateral agent to provide for up to $100 million of term loans, with $35 million drawn at closing, according to an 8-K filing with the Securities and Exchange Commission.

Apollo will be eligible to draw the term B loan of $15 million between July 1, 2023 and Dec. 31, 2023 and the term C loan of $25 million between July 1, 2024 and Dec. 31, 2024, in each case upon the achievement of certain minimum revenue thresholds. A term D loan of $25 million will be eligible to be drawn to finance certain approved acquisitions between June 30, 2022 and June 30, 2024.

Interest is the greater of the Prime rate or 3.25%, in each case plus 400 basis points.

The term loans are interest only from Dec. 21 through Feb. 1, 2027.

On the funding date of each term loan, a facility fee equal to 1% of the applicable loan is payable to the lenders.

Prior to Dec. 21, 2022, the term loans may only be prepaid in full upon a change of control, with payment of 3% prepayment premium. After Dec. 21, 2022, the term loans may be prepaid in full through Dec. 21, 2023 with payment of a 2% prepayment premium, thereafter through Dec. 21, 2024 with payment of a 1% prepayment premium, and thereafter with no prepayment premium. An additional final payment of 4% of the amount of terms loans advanced will be due upon prepayment or repayment of the term loans in full.

The loan agreement contains a minimum liquidity covenant, tested on a maintenance basis, and a minimum revenue covenant, tested quarterly commencing the earlier of Dec. 31, 2023 and the funding date of the term B loan.

Apollo Endosurgery is a medical device company focused on less invasive therapies for the treatment of obesity. It is based in Austin, Tex.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.